NCT04260997已完成不适用
A Randomised, Double-Blinded, Parallel, Placebo-Controlled Study Investigating the Effect of a Probiotic, Lactobacillus Gasseri BNR17, on Body Composition and Weight Management in Overweight Adults.
UAS Labs LLC1 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2020年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 125
- 试验地点
- 1
- 主要终点
- Absolute change from baseline to week 12 in visceral adipose tissue (VAT)
研究概览
简要总结
Lactobacillus gasseri BNR17™ has shown promise in several pre-clinical and randomized controlled clinical trials for weight management outcomes. The current randomized, double-blind, placebo-controlled, parallel-arm trial will further assess L. gasseri BNR17™ on body composition and weight management, and in a study population that is distinct to prior randomized controlled trials on the strain. The study will recruit 126 overweight adult participants who will be randomly assigned to consume L. gasseri BNR17™ or placebo once daily for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Written informed consent;
- •Aged between 25 and 65 years inclusive;
- •Body mass index between 25.0 to 29.9 Kg/m2, inclusive;
- •Waist-hip ratio of ≥0.91 for males and ≥0.81 for females;
- •Sedentary lifestyle, exercising ≤2 times/week;
- •Good general health, as determined by the investigator;
- •Willing to consume the investigational product daily for the duration of the study;
- •Outside the healthy parameters of visceral adipose tissue, defined as 762 cm3 for males and 256 cm3 for females.
排除标准
- •Females who are pregnant, lactating or wish to become pregnant during the study;
- •Participant regularly takes probiotic supplements, or has within the 4-weeks prior to randomisation or plans to during the study;
- •Participant is hypersensitive to any of the components of the investigational product;
- •Participant is severely immuno-compromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or has underwent chemotherapy or radiotherapy within the last year);
- •Participant has Type 1 or Type 2 Diabetes Mellitus;
- •Participant has a history of bariatric surgery;
- •Participant has taken anti-obesity medication or supplements in the 12-weeks prior to randomisation or plans to during the study;
- •Participant is actively or has recently (3 months prior to randomisation) participated in a weight loss program or weight change of 3 kg during the past 3 months;
- •Participant has a life-threatening illness;
- •Participant is on a glucose lowering medication, anti-psychotic drugs or any medication that the investigator determines could impact the results of the study; participant has commenced use, within 3-months of randomisation, anti-hypertensive drugs, anti-depressive drugs, statin or any other medication that the investigator determines could impact the results of the study;
- •Participant has a history of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology (e.g. colon cancer, colitis, Crohn's Disease, Celiac, Endometriosis, prostate cancer) or lactose intolerance;
- •Participant has a recent history of drug and/or alcohol abuse at the time of enrolment;
- •Participant is currently, or planning to participate in another study during the study period;
- •Participant has a history of non-compliance;
- •Participant has taken antibiotics in the 12-weeks prior to randomisation.
结局指标
主要结局
Absolute change from baseline to week 12 in visceral adipose tissue (VAT)
时间窗: 12 weeks
VAT will be assessed using dual energy x-ray absorptiometry
次要结局
- Absolute change from baseline to week 12 in HbA1c(12 weeks)
- Absolute change from baseline to week 12 in hs-CRP(12 weeks)
- Absolute change from baseline to week 12 in total fat mass(12 weeks)
- Absolute change from baseline to week 12 in waist circumference(12 weeks)
- Absolute change from baseline to week 12 in waist-to-hip ratio(12 weeks)
- Absolute change from baseline to week 12 in total lean mass(12 weeks)
- Absolute change from baseline to week 12 in body weight(12 weeks)
- Absolute change from baseline to week 12 in blood glucose(12 weeks)
- Absolute change from baseline to week 12 in blood insulin(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC PatientsUlcerative Colitis Chronic MildUlcerative Colitis Chronic ModerateNCT04102852San Giovanni Addolorata Hospital76
招募中
不适用
Efficacy of Lactobacillus Paracasei LC19 on Type 2 DiabetesType 2 DiabetesNCT06639425Beijing Chao Yang Hospital60
已完成
4 期
Probiotics to Promote Intestinal HealthCommunicable DiseasesInfectionAnti-Infective AgentsTherapeutic UsesPharmacologic ActionsNCT02046512Washington University School of Medicine89
已完成
不适用
Evaluation of the Vaginal Colonization of Two New Lactobacillus Strains After Oral Administration in Healthy VolunteersHealthyNCT05688397AB Biotics, SA48
已完成
不适用
The Efficacy of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy ChildrenAcute Upper Respiratory Tract Infections (Common Cold)NCT02640352Probi AB550